Osteoprotegerin, leptin and IL-6: Association with silent myocardial ischemia in type 2 diabetes mellitus

Diabetes and Vascular Disease Research

Volumn 10, Issue 1, 2013, Pages 25-31

  Guzel, Savas ^a   Seven, Arzu ^b   Kocaoglu, Ali ^c   Ilk, Banu ^c   Guzel, Eda C ^a   Saracoglu, Gamze V ^a   Celebi, Aslan ^c  

^a NAMIK KEMAL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Taksim Training and Research Hospital   (Turkey)

Author keywords

coronary artery disease; Diabetes mellitus; IL 6; leptin; myocardial ischemia; osteoprotegerin; type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; LEPTIN; OSTEOPROTEGERIN;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HUMAN; MALE; MYOCARDIAL PERFUSION IMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RISK; SEX DIFFERENCE; SILENT MYOCARDIAL ISCHEMIA; SMOKING; VASCULITIS;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EXERCISE TEST; FEMALE; HUMANS; INTERLEUKIN-6; LEPTIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; OSTEOPROTEGERIN; REGRESSION ANALYSIS;

EID: 84871827823     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112440815     Document Type: Article

References (43)

1. Mazzini MJ, Schulze PC. Proatherogenic pathways leading to vascular calcification. Eur J Radiol. 2006 ; 57: 384-389 (Pubitemid 43254919)
2. Koistinen MJ. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. BMJ. 1990 ; 301: 92-95 (Pubitemid 20223591)
3. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in non-insulin dependent diabetes mellitus. Am J Cardiol. 1997 ; 79: 134-139
4. Diagnosis and classification of diabetes mellitus. Diab Care. 2010 ; 33: S62-69
5. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atheroscler. 2009 ; 204: 321-329
6. Venuraju SM, Yerramasu A, Corder R, et al. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010 ; 55: 2049-2061
7. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circul. 2002 ; 106: 1192-1194 (Pubitemid 34988634)
8. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circul. 2004 ; 109: 2175-2180 (Pubitemid 38625393)
9. Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008 ; 51: 627-633 (Pubitemid 351193104)
10. Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diab Care. 2006 ; 29: 1664-1666
11. Avignon A, Sultan A, Piot C, et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diab Care. 2005 ; 28: 2176-2180 (Pubitemid 41242464)
12. Anand DV, Lahiri A, Lim E, et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006 ; 47: 1850-1857
13. Lee JE, Choi YK, Seo HA, et al. Impact of ENPP1 and MMP3 gene polymorphisms on aortic calcification in patients with type 2 diabetes in a Korean population. Diab Res Clin Pract. 2010 ; 88: 87-96
14. Reilly MP, Iqbal N, Schutta M, et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab. 2004 ; 89: 3872-3878 (Pubitemid 39071487)
15. Xiang GD, Xu L, Zhao LS, et al. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diab. 2006 ; 55: 2126-2131 (Pubitemid 44509988)
16. Araz M, Celen Z, Akdemir I, et al. Frequency of silent myocardial ischemia in type 2 diabetic patients and the relation with poor glycemic control. Acta Diabetolog. 2004 ; 41: 38-43 (Pubitemid 38849825)
17. Gokcel A, Aydin M, Yalcin F, et al. Silent coronary artery disease in patients with type 2 diabetes mellitus. Acta Diabetolog. 2003 ; 40: 176-180 (Pubitemid 37548150)
18. Janand-Delenne B, Savin B, Habib G, et al. Silent myocardial ischemia in patients with diabetes: Who to screen. Diab Care. 1999 ; 22: 1396-1400 (Pubitemid 29418229)
19. Knudsen ST, Foss CH, Poulsen PL, et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003 ; 149: 39-42 (Pubitemid 36874202)
20. Yaturu S, Rains J, Jain SK. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. Cytokine. 2008 ; 44: 168-171
21. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001 ; 86: 631-637 (Pubitemid 32207471)
22. Gannagé-Yared MH, Fares F, Semaan M, et al. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol Oxf. 2006 ; 64: 652-658 (Pubitemid 43775003)
23. Gannagé-Yared MH, Yaghi C, Habre B, et al. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: Results from both cross-sectional and interventional study. Eur J Endocrinol. 2008 ; 158: 353-359 (Pubitemid 351405000)
24. Oh SY, Rhee EJ, Lee WY, et al. Relationship between serum osteoprotegerin levels and insulin resistance, cardiovascular risk, metabolism in type 2 diabetic patients. Korean J Med. 2005 ; 68: 168-177
25. Hofbauer LC, Schoppet M. Osteoprotegerin: A link between osteoporosis and arterial calcification?. Lancet. 2001 ; 358: 257-259 (Pubitemid 32738960)
26. Anand DV, Lim E, Darko D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol. 2007 ; 50: 2218-2222
27. Jung CH, Lee WY, Kim SY, et al. The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol. 2010 ; 47: 145-152
28. Rasmussen LM, Tarnow L, Hansen TK, et al. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol. 2006 ; 154: 75-81 (Pubitemid 43250739)
29. Avignon A, Sultan A, Piot C, et al. Osteoprotegerin: A novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diab Care. 2007 ; 30: 2934-2939 (Pubitemid 350083147)
30. Singh DK, Winocour P, Summerhayes B, et al. Low serum osteoprotegerin levels in normoalbuminuric type 1 diabetes mellitus. Acta Diabetol. 2010 ; 47: 105-110
31. Jørgensen GM, Vind B, Nybo M, et al. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. Eur J Endocrinol. 2009 ; 161: 95-101
32. Schoppet M, Kavurma MM, Hofbauer LC, et al. Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. Biochem Biophys Res Commun. 2011 ; 407: 103-107
33. Zhang J, Fu M, Myles D, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002 ; 521: 180-184 (Pubitemid 34628481)
34. Iribarren C, Husson G, Go AS, et al. Plasma leptin levels and coronary artery calcification in older adults. J Clin Endocrinol Metab. 2007 ; 92: 729-732
35. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 2002 ; 13: 18-23 (Pubitemid 36734011)
36. Wallace AM, MacMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circul. 2001 ; 104: 3052-3056 (Pubitemid 34014056)
37. Lubaszewski W, Kawecka-Jaszcz K, Czarnecka D, et al. Silent myocardial ischaemia in patients with essential arterial hypertension and non-insulin dependent diabetes mellitus. J Hum Hypertens. 1999 ; 13: 309-313 (Pubitemid 29248541)
38. Nalbantgil I, Onder R, Nalbantgil S, et al. The prevalence of silent myocardial ischaemia in patients with white-coat hypertension. J Hum Hypertens. 1998 ; 12: 337-341 (Pubitemid 28274365)
39. Tsioufis C, Aggelis A, Dimitriadis K, et al. Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: Integrating vascular dysfunction. Expert Opin Ther Targets. 2011 ; 15: 1347-1353
40. Rutter MK, MacComb JM, Brady S, et al. Silent myocardial ischemia and microalbuminuria in asymptomatic subjects with non-insulin-dependent diabetes mellitus. Am J Cardiol. 1999 ; 83: 27-31 (Pubitemid 29036642)
41. Earle KA, Mishra M, Morocutti A, et al. Microalbuminuria as a marker of silent myocardial ischaemia in IDDM patients. Diabetol. 1996 ; 39: 854-856 (Pubitemid 26228116)
42. Inoguchi T, Yamashita T, Umeda F, et al. High incidence of silent myocardial ischemia in elderly patients with non insulin-dependent diabetes mellitus. Diab Res Clin Pract. 2000 ; 47: 37-44
43. Cosson E, Guimfack M, Paries J, et al. Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events?. Diab Metab. 2003 ; 29: 470-476 (Pubitemid 37474258)